Guard Therapeutics: Phase IIb study POINTER ends in failure - Redeye
Redeye comments on the disappointing news that Guard Therapeutics' drug candidate RMC-035 did not meet its endpoints in its phase IIb study POINTER. We anticipate a share price decline of 80-90% today.
ANNONS
Redeye comments on the disappointing news that Guard Therapeutics' drug candidate RMC-035 did not meet its endpoints in its phase IIb study POINTER. We anticipate a share price decline of 80-90% today.